Kornimate/medical-research-clean huggingface dataset:
smartphone twelve lead electrocardiogram utility in st-elevation myocardial infarction

Conditions: STEMI

Summary: is the smartphone ecg (electrocardiogram) an acceptable replacement for a standard ecg in the identification of stemi (st elevation myocardial infarction).

the primary objective of this study is to determine if the smartphone electrocardiogram (ecg) is an acceptable replacement for a standard ecg in the identification of st elevation myocardial infarction (stemi). toward this objective, this study involves the following: obtain simultaneous recordings of a standard 12-lead ecg and the iphone "12-lead equivalent" ecg on patients presenting with chest pain in which the stemi protocol was activated. obtain simultaneous recordings of a standard 12-lead ecg and the iphone "12-lead equivalent" ecg on patients presenting to the emergency department for evaluation of chest pain, not necessarily presenting with stemi. reading of ecgs (standard 12-lead and iphone) by three independent cardiologists, who are blinded to the initial clinical ecg readings, the type of ecg equipment used, and the patient's clinical information. assess the operational feasibility of using the smartphone to obtain "12-lead equivalent" ecg recordings in patients suspected to have stemi, and determine the possibility of pooling the data obtained from this study with data from other institutions conducting identical studies, and developing a future and statistical analysis plan to compare the sensitivity, specificity, positive predictive value and the negative predictive power of the iphone ecg, using a paired standard 12-lead ecg as the gold standard. there will be no therapeutic interventions. a single research-related procedure will be required, i.e., an iphone ecg. effort will be made to ensure that the performance of this procedure will not delay any treatment and/or diagnostic procedures that are part of usual or specialized care that the patient requires. the individual patient's participation in the study will actually be only one day, i.e., the day the informed consent is obtained and the two comparison ecgs will be done.

Eligibility criteria:
inclusion criteria: * ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures (patient or legally acceptable representative). * symptoms of chest pain upon presentation exclusion criteria: * inability or refusal of the patient and/or the patient's legally-acceptable representative to provide written informed consent for any reason. * other conditions that in the opinion of the principal investigator or co-investigator(s) may increase risk to the subject and/or compromise the quality of the clinical trial.

Keywords: myocardial infarction ischemia myocardial ischemia heart diseases cardiovascular diseases vascular diseases
pronator quadratus repair after volar plating of distal radius fractures

Conditions: Forearm Pronation Strength Recovery

Summary: investigation of the influence of the pronator quadratus (pq) muscle repair following volar plate fixation of distal radius fractures with regard to the forearm pronation strength. during the early recovery period of 3 months an improvement of pronation strength and functional scorings was hypothesized for the pq repair when compared to no repair. randomization of the patients in two groups ( pq repair and no repair) and follow-up examinations after 6 and 12 weeks included bilateral isometric pronation strength measurement, range of motion, the quickdash and the mayo-wrist-score, and a visual analogue scale (vas)

investigation of the influence of the pronator quadratus (pq) muscle repair following volar plate fixation of distal radius fractures with special regards to the forearm pronation strength. during the early recovery period of 3 months an improvement of pronation strength and functional scorings was hypothesized for the pq repair when compared to no repair. therefore the patients are randomized to group a = pq repair and group b = no repair. follow-up examinations after 6 and 12 weeks are scheduled included bilateral isometric pronation strength measurement, range of motion, the quickdash and the mayo-wrist-score, and a visual analogue scale (vas)

Eligibility criteria:
inclusion criteria: * isolated, closed fractures of the distal radius * fractures type a2 to b2 according to the ao fracture classification system * primary volar locking plate osteosynthesis within 7 days after trauma exclusion criteria: * concomitant fractures of the affected upper extremity * intra-articular distal radius fractures ( type c) * concomitant neurovascular injuries * preexisting neurological illnesses * initial external fixation
macrobiotic diet and flax seed: effects on estrogens, phytoestrogens, & fibrinolytic factors

Conditions: Cardiovascular Diseases; Osteoporosis; Breast Cancer; Endometrial Cancer

Summary: this study will assess whether alternative, high phytoestrogen dietary interventions result in favorable effects on biological parameters that have been associated with hormone-dependent cancers, cardiovascular disease, and osteoporosis.

broad health effects of endogenous and exogenous estrogens on diseases of aging, including hormone-dependent cancers, cardiovascular disease, and osteoporosis, are generally recognized. for example, estrogen replacement therapy (ert) may increase the risk of subsequent breast and endometrial cancer, but also decreases the risk of coronary disease and fractures. because of the increased cancer risk, many women seek out alternatives to ert. phytoestrogens, plant compounds that have estrogenic effects, have been a focus of interest as an alternative to ert. the isoflavones and lignans are two major classes of phytoestrogens that occur in the food supply. among the former, soy foods have attracted much interest, while among the latter, whole grains and seeds are sources in a typical diet. more specifically, women consuming a macrobiotic diet have been observed to have extremely high levels of phytoestrogen metabolites in their urine, perhaps 10 to 20 times that seen in women consuming an omnivorous diet. proponents of a macrobiotic diet have proposed that it is beneficial in the context of cancer therapy, as well as for the prevention and treatment of cardiovascular disease. this study will investigate, in a randomized, three-arm study, the effects of two interventions that are high in phytoestrogens on various parameters related to estrogen metabolism and fibrinolysis. approximately 120 women will be randomized to receive an american heart association (aha) step 1 diet, an aha step 2 diet + 10 g/day flax seed, or a macrobiotic dietary intervention. blood and urine samples will be drawn at baseline, and at three, six, nine, and twelve months, to examine both short and long-term effects of these interventions. outcomes include blood and urine levels of total estrogens and estradiol, and related metabolites; antigens to plasminogen activator inhibitor-1 (pai-1) and tissue plasminogen activator (t-pa), fibrin d-dimer, and von willebrand factor; and endothelial function as measured by high-resolution ultrasound. blood levels of antioxidant vitamins and retinoids will also be examined. this study should provide information on whether these alternative, high phytoestrogen dietary interventions result in favorable effects on these biological parameters that are related to risk of major diseases of aging.

Eligibility criteria:
inclusion criteria: this trial is recruiting in the new york metro area only * postmenopausal * weight within 90% to 120% of ideal body weight

Keywords: cardiovascular diseases osteoporosis breast cancer endometrial cancer
pulmonary functions in sickle cell disease: response to acu-tens

Conditions: Sickle Cell Disease

Summary: pulmonary complications are common in sickle cell disease patients. respiratory training using inspiratory muscle trainer (imt) is usually a good choice to improve these complications. recently, acupuncture like transcutaneous electrical nerve stimulation (ac-tens) may also improve these complications.

sickle cell disease patients whose number will be forty patients will be divided to group i who will trained with imt (threshold inspiratory muscle training) and treated with ac-tens (the number of patients will be 20) or group ii who will trained with imt (the number of patients will be 20) . the number of sessions per week will be three sessions for imt or ac-tens for 12 weeks. the imt will be performed for six sets of respiratory training cycles and the set will contain 10 respiratory cycles. also the session of ac-tens will be 45 minute on bilateral ex-b1 acupoint. the parameters of ac-tens will be four hertz and 200 microsecond pulse duration.

Eligibility criteria:
inclusion criteria: * sickle cell disease patients * non obese patients exclusion criteria: * patients with any systemic or chest or renal or hepatic or neurological diseases * women with lactation or pregnancy * patients atacks of vasoocclusive crisis
efficacy of steroid versus steroid plus cyclophosphamide for severe henoch-schoenlein purpura

Conditions: Henoch-Schoenlein Purpura

Summary: henoch-schonlein purpura is a leucocytoclastic systemic vasculitis involving small vessels with the deposition of immune complexes containing iga. it is characterized by the association of skin, joint and gastrointestinal manifestations. even though the evolution is usually simple, some patients, especially adults, may have severe visceral involvement including heart, lung, brain and renal disease. the best treatment is currently unknown. this study will test the safety and efficacy of steroids associated or not with cyclosphosphamide to treat the acute lesions and to prevent the development of chronic lesions.

the protocol test the role of 2 modalities of treatment (steroid vs. steroid and cyclophosphamide) for severe systemic form of henoch-schonlein purpura. the severe forms include extracapillary glomerulonephritis, myocarditis, pneumonitis, occult involvement, severe gastro-intestinal bleeding. no other randomized trial has been performed in adult patient for this indication.

Eligibility criteria:
inclusion criteria: * patients with henoch-schoenlein purpura * patient's age \> 18 years exclusion criteria: * patient presenting a purpura rheumatoid the diagnosis of which is confirmed by the histology presenting at least a visceral infringement(achievement) making consider the affection as engraves(burns) * of 18 or more years old patient * patient capable of understanding(including) the advantages and the risks of the try * patient having given his assent lit in writing

Keywords: vasculitis cyclophosphamide renal failure
lenalidomide in subjects with intermediate2 or high mds associated with a deletion (del) 5q [31]

Conditions: Myelodysplastic Syndromes

Summary: we are evaluating the incidence of significant hematological response, according to iwg criteria including cr, pr or, major hi, (hi-e, hl-n,or hl- p), and cytogenetic response of patients diagnosed with intermediate-2 or high-risk (international prognostic scoring system \[ipss\]) mds with a deletion (del) 5q\[31\]

subjects meeting all inclusion and exclusion criteria will receive lenalidomide lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on days 1-21, every 4 weeks. bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and when clinically indicated/for assessment of disease progression) evaluations subjects may participate in the study for up to 52 weeks ( in patients still responding after 52 weeks, the drug wil continue to be supplied).

Eligibility criteria:
inclusion criteria: * age \> 18 years at the time of signing the informed consent form * mds with ipss scores int-2 or high with deletion 5q(31) * prior thalidomide allowed * documented diagnosis of mds (ra, rars, raeb, raeb-t and cmml with wbc \< 13,000/mm3 according to fab classification) that meets ipss criteria for intermediate-2 or high-risk disease and has an associated del 5q\[31\] (the deleted chromosomal region must include 5q\[31\]), with or without additional cytogenetic abnormalities exclusion criteria: * pregnant or lactating females * prior therapy with lenalidomide * mds with ipss scores low or int-1 * clinical neuropathy of greater than grade 2 * proliferative (wbc ≥ 13,000/ml) chronic myelomonocytic leukemia (cmml) * recombinant human erythropoietin (rhuepo) therapy received within 28 days * use of androgens other than for treating hypogonadism

Keywords: mds int-2mds high riskdeletion 5q[31]lenalidomide
primary biliary cirrhosis: investigating a new treatment option using ni-0801, an anti-cxcl10 monoclonal antibody

Conditions: Primary Biliary Cirrhosis

Summary: the purpose of the study is to assess safety and efficacy of multiple doses of ni-0801 in primary biliary cirrhosis patients with an inadequate response to ursodeoxycholic acid.


Eligibility criteria:
inclusion criteria: * proven primary biliary cirrhosis (pbc), as demonstrated by the presence of at least 2 of the following 3 diagnostic factor (history of increased alkaline phosphatase levels for at least 6 months; positive serum ama titer; liver biopsy consistent with pbc) * elevated liver enzyme levels at screening * have given written informed consent exclusion criteria: * screening bilirubin \> 2.9 mg/dl (50 μmol/l) * screening creatinine clearance \< 80 ml/min * history or presence of hepatic decompensation (e.g., esophageal variceal bleeding, hepatic encephalopathy, or ascites) * positive serology result for human immunodeficiency virus (hiv), hepatitis b or c * known or previous diagnosis of malignancy * presence of any active infection * previous history of active tb within 12 months of screening
work of breathing assessment in triage scale

Conditions: Shortness of Breath; Respiratory Symptoms; Cough; Difficulty Breathing; Hypoxemia

Summary: the proposed research study will be a prospective observational study designed to validate the canadian triage assessment scale (ctas) in regard to work of breathing in patients in the emergency department. the investigators will assess inter-rater agreement between nurses \& emergency physicians for assessment of work of breathing.

investigators will enroll a convenience sample of consenting patients who present to the emergency department with a chief complaint related to respiratory symptoms, including shortness of breath, cough, difficulty breathing, hypoxemia, or any other respiratory related complaint. following consent and in a blinded fashion, the nurse \& emergency physician will be asked to evaluate the patient's work of breathing into three subjective categories: mild, moderate, or severe. the two evaluators will not be aware of the others evaluation of the patient. evaluators will also be asked to predict the patients likely need for intervention \& disposition. subsequently, investigators will perform a chart review to determine the patient's clinical interventions, outcomes, and dispositions, and evaluate the assessment of the patients work of breathing.

Eligibility criteria:
inclusion criteria: * 18 years of age of older * presenting to the emergency department with a chief complaint of any type of respiratory symptom. exclusion criteria: * under 18 years of age * refusal to consent to study * incarcerated patients * pregnant patients * unable to complete survey due to clinical instability, severe pain, or disorientation determined by a study physician.

Keywords: emergency room respiratory assessment work of breathing
a phase iii study of brimonidine tartrate ophthalmic solution, 0.15% in patients with open-angle glaucoma or ocular hypertension

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Summary: the primary objective of this study is to compare the safety and efficacy of brimonidine tartrate ophthalmic solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
* patients of any race * two (2) years of age or older * of either sex * diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)or ocular hypertension

Keywords: open-angle glaucoma ocular hypertension
serum esnophilic cationic protein level as diagnostic marker in cow milk protein allergy infants

Conditions: Cow Milk Allergy

Summary: characterize the degree of the activation of serum eosinophilc cationic protein (secp) by measuring its level and establishing whether it is a useful parameter in monitoring oral cow's milk allergy measure the mpv and nlr levels in infants with cmpa and to determine the suitability of these parameters as biomarkers in diagnosis of cmpa.

cow's milk protein allergy (cmpa) is the most common cause of food allergies in children with incidence estimated as 2% to 7.5% in the first year of life and is characterized by an inflammatory reaction to milk proteins, formula and exclusively breast-fed babies can develop cmpa. the immunologic mechanism behind the development of cmpa is not yet clear. however, it is clear that cmpa is caused by ige- as well as non-ige-mediated immune reactions, ige-mediated cmpa is better described and it is typically immediate, type 1 hypersensitivity (minutes to 2 hours after consumption of cow's milk) while non ige- mediated cmpa is delayed, type 4 hypersensitivity. a diverse range of symptoms of variable intensity in infants. combinations of immediate and delayed reactions to the same allergen may occur in the same patient, symptoms and signs related to cmpa may involve many different organ systems, mostly the skin and the gastro- intestinal and respiratory tracts. the involvement of two systems increases the probability of cmpa, whereas some symptoms are more likely to be present in infant with a positive test for cmp-specific ige (eg, angioedema, atopic eczema); however, there is a large overlap. the same symptoms may appear in cmp ige-positive and ige-negative patients, particularly in infant with gastrointestinal manifestations. studies in unselected infants with cmpa show that approximately half of them have atopic eczema, and 25% to 50% are affected by some gastrointestinal tract involvement whereas other clinical manifestations are less common. it is important to accurately diagnose cmpa to avoid the consequences of either under- or overdiagnosis, skin prick test and serum specific ige tests are helpful for diagnosis, mainly in ige-mediated forms . on the other hand, in cases of cmpa with gastrointestinal chronic signs and symptoms, skin prick test and specific ige tests are usually negative. this is the reason why the only reliable method of diagnosis in such cases is a food challenge that need to be done in hospital and could be also dangerous, this explain why there is a growing interest to find new biomarkers for diagnosis and follow up.eosinophil cationic protein (ecp) is a cytotoxic protein released from eosinophils upon activation the measurement of ecp levels can be used as a non invasive indicator to detect active inflammation in the body.

Eligibility criteria:
inclusion criteria: - all infants (0-12 month) suspected with cmpa exclusion criteria: * infants with genetic, metabolic, haematological, or infectious (e.g. :infectious gastroenteritis) diseases will be excluded from the study
correlation between clinical neurological biomarkers and rehabilitation outcome

Conditions: Stroke

Summary: our study purpose is to evaluate the predictive power of various clinical, neurophysiological, and neuroimaging biomarkers-acquired and analyzed using advanced and integrated techniques-on motor functional recovery and disability post-stroke. the goal is to construct an integrated individual biomarker algorithm with a high predictive value for outcomes.

ability to predict post-stroke individual recovery still represents an important challenge to develop personalized and effective neurorehabilitation strategies. the aim of this study is to verify the predictive power of different clinical, neurophysiological and neuroimaging biomarkers in combination, acquired and analysed using advanced, integrated techniques, on functional motor recovery and post-stroke disability. patients with ischemic or hemorrhagic stroke and hemiparesis are subsequently enrolled and undergo multimodal assessment that includes measures spanning 4 assessment categories: demographic/medical history, clinical biomarkers, neurophysiological biomarkers (motor evoked potentials, high-density eeg), neuroimaging biomarkers (infarct volume, corticospinal tract injury) at t0 (from 14 to 30 days post-stroke), t1 (after 2 months of intensive rehabilitation treatment) and t2 (4-6 months after discharge). primary endpoint is change in arm fugl-meyer score. secondary endpoints are changes in lower limb fugl meyer motor, nine hole peg test, national institute of health stroke scale, mrs rankin scale, modified barthel index scores. multivariate analyses will indicate which biomarkers at baseline have the greatest value to predict significant changes in primary and secondary endpoints at t1 and t2. a model incorporating measures of clinical, neurophysiological and neuroimaging biomarkers could best predict individual treatment-induced behavioral gains and therefore allow to plan a "tailor-made" rehabilitation project, select rehabilitation therapy, appropriate allocation of time and human resources and stratify clinical trial enrollees.

Eligibility criteria:
inclusion criteria: * first stroke in the middle cerebral artery territory. * ischemic or hemorrhagic stroke (7-30 days post-acute event). * upper limb plegia or paresis. * both genders, aged \>18 years. * ability to provide informed consent by the patient or caregiver/responsible relative. exclusion criteria: * previous stroke. * stroke in territories other than the middle cerebral artery. * inability to provide informed consent. * contraindications to tms or mri. * history of cancer in the past two years. * presence of other neurological conditions interfering with biomarkers
cell saver use in bilateral total hip arthroplasty (tha)

Conditions: One-stage Bilateral Total Hip Replacement

Summary: this study will investigate the efficacy of using cell saver during bilater total hip arthroplasty


Eligibility criteria:
inclusion criteria: * subject is over 21 years of age * subject with bilateral degenerative disease of hips who are candidate for one-stage bilateral tha * subject willing and able to provide written informed consent exclusion criteria: * subject with significant comorbidities identified by charleston index of ≥ 3 * subject with malignancy * subject with history of heart disease, myocardial infarction, pulmonary insufficiency, pulmonary embolus, documented fat emboli syndrome, adult respiratory distress syndrome, documented patent ductus arteriosus or septal defect, chronic renal failure and/or acute hepatic failure or chirhosis * subjects with hematologic disorders such as anemia (hb \< 10 g/dl) and sickle cell disease, acquired or congenital coagulopathies, acquired or congenital bleeding disorders, * subject who received anticoagulant such as aspirin or warfarin (coumadin) or antiplatelet agents such as clopidogrel (plavix) within 7 days of surgery * subject who received hemostatic agents such as tranexamic acid and aprotinin * subjects utilizing acute normovolumic haemodilution * subject is not permitted to remain without his/her anti-coagulant regimen (eg plavix) for 48 hours postoperatively * subject is known to be pregnant. * subject has erythropoietin agonist/stimulating agent within 90 days prior to surgery. * presence of contaminants such as urine, fat, bowel contents, and most importantly infection in the operative field * presence of vasoactive drugs such as papaverine in the operative field